drugset
drugset / Trial / NCT00684567

Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)

NCT00684567 ↗

Phase 2 Completed 30 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of combination therapy of radiotherapy and temozolomide ("concomitant radiotherapy phase"), and then temozolomide monotherapy ("monotherapy phase"), in patients with newly diagnosed glioblastoma multiforme. Progression free survival and response rate will also be calculated.

Timeline

Start
2005-09-27
Primary completion
2007-10-31
Completion
2007-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 150 mg/m2 —
Subject Temozolomide Small molecule 200 mg/m2 —

Indications

glioblastoma